Micar Innovation

Micar Innovation, also known as Micar21, is a Sofia-based biotechnology company specializing in AI-driven, structure-based in silico drug discovery. The company utilizes a multidisciplinary approach that combines molecular dynamics simulations, quantum chemistry, and computational biology to identify and optimize novel drug candidates. Their proprietary discovery engine integrates advanced GPU-accelerated computing to perform complex tasks, including pharmacophore and docking screens, free energy perturbation, and genetic screen analysis. By avoiding reliance on a single methodology, the firm leverages state-of-the-art computational techniques to accelerate preclinical research and improve the cost-effectiveness of identifying active compounds for various therapeutic areas.

The company operates under a unique Build-to-Buy business model, partnering with major biopharmaceutical firms and academic researchers to create specialized spin-off ventures focused on translation therapies. This collaborative framework allows partners to de-risk development while Micar21 executes discovery programs for unmet medical needs, including rare genetic diseases, neurodegenerative conditions, and chronic pain. By fostering relationships that span from initial hit identification to preclinical stages, Micar21 aims to deliver first-in-class and best-in-class therapeutics faster than traditional methods, ultimately seeking to improve societal health outcomes through these targeted drug development partnerships.